Rifampicin
From Wikipedia, the free encyclopedia
 |
|
|
Rifampicin
|
|
| Systematic (IUPAC) name | |
| 5,6,9,17,19,21-Hexahydroxy-23-methoxy- 2,4,12,16,18,20,22-heptamethyl- 8-[N-(4-methyl-1-piperazinyl)formimidoyl]- 2,7-(epoxypentadeca[1,11,13]trienimino)- naphtho[2,1-b]furan-1,11(2H)-dione 21-acetate |
|
| Identifiers | |
| CAS number | |
| ATC code | J04 |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C43H58N4O12 |
| Mol. mass | 822.94 g/mol |
| Pharmacokinetic data | |
| Bioavailability | 90 to 95% |
| Metabolism | Hepatic and intestinal wall |
| Half life | 6 to 7 hours |
| Excretion | 15 to 30% renal 60% faecal |
| Therapeutic considerations | |
| Pregnancy cat. |
C(AU) |
| Legal status | |
| Routes | Oral, IV |
Rifampicin (INN) (pronounced /rɪˈfæmpəsɪn/) or rifampin (USAN) is a bactericidal antibiotic drug of the rifamycin group.[1] It is a semisynthetic compound derived from Amycolatopsis rifamycinica (formerly known as Amycolatopsis mediterranei and Streptomyces mediterranei). Rifampicin may be abbreviated RIF, RMP, RD, RA or R. It is also known as rifaldazine, R/AMP, and Rofact (in Canada.) There are various types of rifamycins from which this is derived, but this particular form, with a 4-methyl-1-piperazinaminyl group, is by far the most clinically effective.
Contents |
[edit] Indications
Rifampicin was introduced in 1967,[2] as a major addition to the cocktail-drug treatment of tuberculosis and inactive meningitis, along with isoniazid, ethambutol, and streptomycin. There is no generic form. It requires a prescription in industrial North America, but is not a controlled substance. It must be administered regularly daily for several months without break otherwise the risk of drug-resistant tuberculosis is greatly increased.[2] In fact, this is the primary reason that it is used in tandem with the three aforementioned drugs, particularly isoniazid.[3]
Rifampicin is typically used to treat Mycobacterium infections, including the aforementioned tuberculosis and leprosy; it also has a role in the treatment of methicillin-resistant Staphylococcus aureus (MRSA) in combination with fusidic acid. It is used in prophylactic therapy against Neisseria meningitidis (meningococcal) infection. Further, it has been used with Amphotericin B in largely unsuccessful attempts to treat primary amoebic meningoencephalitis caused by Naegleria fowleri.
It is also used to treat infection by Listeria species, Neisseria gonorrhoeae, Haemophilus influenzae and Legionella pneumophila. For these non-standard indications, sensitivity testing should be done (if possible) before starting rifampicin therapy. Rifampicin resistance develops quickly during treatment and rifampicin monotherapy should not be used to treat these infections — it should be used in combination with other antibiotics. With multidrug therapy (MDT) used as the standard treatment of leprosy, rifampicin is always used in combination with dapsone and clofazimine.
Enterobacteriaceae, Acinetobacter and Pseudomonas species are intrinsically resistant to rifampicin[citation needed].
[edit] Pharmacodynamics (mechanism of action)
Rifampicin inhibits DNA-dependent RNA polymerase in bacterial cells by binding its beta-subunit, thus preventing transcription to RNA and subsequent translation to proteins. Its lipophilic nature makes it a good candidate to treat the meningitis form of tuberculosis, which requires distribution to the central nervous system and penetration through the blood-brain barrier.
Rifampin acts directly on messenger RNA synthesis. It inhibits only prokaryotic DNA-primed RNA polymerase, especially those that are Gram-stain-positive, such as Mycobacterium tuberculosis, which is slightly such. In fact, evidence shows that in vitro DNA treated with concentrations 5000 times higher than normal dosage remained unaffected; in vivo eukaryotic specimen's RNA and DNA polymerases suffered few problems as well.[3][4] Much of these Gram-positive bacteria’s membrane is mycolic acid complexed with peptidoglycan which allows easy movement of the drug into the cell. Rifampicin interacts with the β subunit of RNA polymerase when it is in an α2β trimer. This halts mRNA transcription, therefore preventing translation of polypeptides.[3] It should be made clear, however, that it cannot stop the elongation of mRNA once binding to the template-strand of DNA has been initiated.[5] The Rifampin-RNA Polymerase complex is extremely stable and yet experiments have shown that this is not due to any form of covalent linkage. It is hypothesized that hydrogen bonds and π-π bond interactions between naphthoquinone and the aromatic amino acids are the major stabilizers, though this requires the oxidation of naphthohydroquinone which is found most commonly in Rifampin. It is this last hypothesis that explains the explosion of multi-drug-resistant bacteria: mutations in the rpoB gene that replace phenylalanine, tryptophan, and tyrosine with non-aromatic amino acids result in poor bonding between Rifampin and the RNA polymerase.[3]
Rifampin-resistant bacteria produce RNA Polymerases with subtly different β subunit structures which are not readily inhibited by the drug.[6] In molecular biology research, plasmids containing Rifampicin (abbrev. Rif) resistant gene are often used for colony screening. Many plasmids containing Rif resistant genes are commercially available to researchers.
[edit] Adverse effects
Adverse effects are chiefly related to the drug's hepatitis, and patients receiving rifampicin often undergo liver function tests including aspartate aminotransferase (AST). The dosage cannot be given in amounts higher than 600mg (average for a healthy adult) or the patient risks serious liver damage due to Rifampin's hepatotoxicity.[7]
Not only is hepatotoxicity a problem, but Rifampin has a slew of adverse reactions when taken concurrently with other drugs]].[7] People with apoplectic problems, thrombosis, or who have an increased risk of myocardial infarction have to be especially cautious when using Rifampin because the drug can easily reduce the potency of most of the common anticoagulants such as Acenocoumarol and Warfarin; in fact, the dosage of these cardiovascular drugs must be increased up to three times to compensate.[8] Rifampin is an effective liver enzyme-promoting chemical - consequently, these enzymes can easily catabolize anticoagulants. Specifically, it is a potent inducer of hepatic cytochrome P450 enzymes (such as CYP2D6 and CYP3A4) and will increase the metabolism of many other drugs that are cleared by the liver through this enzyme system. This results in numerous drug interactions such as reduced efficacy of hormonal contraception. There are other mechanisms that have been proposed.
The most common unwanted effects are fever, gastrointestinal disturbances, rashes and immunological reactions. Liver damage, associated with jaundice, has also been reported and in some rare cases has led to death.
Taking rifampicin can cause certain bodily fluids, such as urine and tears, to become orange-red in color, a benign but sometimes frightening side-effect. This may permanently stain soft contact lenses. It also may be excreted in breast milk, therefore breast feeding should be avoided.
Rifampicin is eliminated chiefly through the secretion of bile into the GI tract. In short
- Hepatitis
- Respiratory syndrome- breathlessness'
- Cutaneous syndrome - flushing, pruritus+ rash , redness and watering of eyes.
- Flu syndrome - with chills ,fever , headache , malaise and bone pain
- Abdominal syndrome - nausea, vomiting , abdominal cramps with or without diarrhoea
[edit] Pharmacokinetics
Orally administered Rifampin results in peak plasma concentrations in about 2 to 4 hours. Aminosalicyclic acid may significantly reduce absorption of Rifampin, and peak concentrations may not be reached. If these two drugs must be used concurrently, they must be given separately with an interval of 8 to 12 hours between administrations.
Rifampin is easily absorbed from the gastrointestinal tract and its ester functional group is quickly hydrolyzed in the bile and catalyzed by a high pH and substrate-specific enzymes called esterases. After about 6 hours, almost all of the drug is deacetylated. Even in this deacetylated form, Rifampin is still a potent antibiotic; however, it can no longer be reabsorbed by the intestines and it is subsequently eliminated from the body. Only about 7% of the administered drug will be excreted unchanged through the urine, though urinary elimination accounts for only about 30% of the dose of the drug that is excreted. About 60% to 65% is excreted through the feces.
The half-life of Rifampin ranges from 1.5 to 5 hours, though hepatic impairment will significantly increase it. Food consumption, on the other hand, inhibits absorption from the GI tract, and the drug is more quickly eliminated.
Distribution of the drug is high throughout the body, and reaches effective concentrations in many organs and body fluids, including the CSF. This high distribution is the reason for the orange-red color of the saliva, tears, sweat, urine, and feces. About 60% to 90% of the drug is bound to plasma proteins.[5]
[edit] Preparations
In Bulgaria it is marketed as Tubocin (by Actavis/Balkanpharma), in Israel as Rimactan (Sandoz) and in Romania as Sinerdol (Sicomed). In the UK marketed as Rifadin (Aventis), Rimactan (Sandoz), Rifater a combination with isoniazid and pyrazinamide (Aventis), Rifinah a combination with isoniazid (Aventis) and Rimactazid a combination with isoniazid (Sandoz). In the U.S. as Rifadin (Aventis), Rifater combination with isoniazid and pyrazinamide (Aventis), Rimactane (Novartis). In India Rifampicin is available as R-Cinex 600 (Lupin Ltd). Its a combination of Rifampicin and Isoniazid.
[edit] References
- ^ Masters, Susan B.; Trevor, Anthony J.; Katzung, Bertram G. (2005). Katzung & Trevor's pharmacology. New York: Lange Medical Books/McGraw Hill, Medical Pub. Division. ISBN 0-07-142290-0.
- ^ a b Long, James W. (1991). Essential Guide to Prescription Drugs 1992. New York: HarperCollins Publishers, pp. 925-929. ISBN 0-06-273090-8.
- ^ a b c d Erlich, Henry, W Ford Doolittle, Volker Neuhoff, and Et Al . Molecular Biology of Rifomycin. New York, NY: MSS Information Corporation, 1973. pp. 44-45, 66-75, 124-130.
- ^ Coulson, Christopher J. "Bacterial RNA-Polymerase - Rifampin as Antimycobacterial." Molecular Mechanisms of Drug Action. 2nd ed. Bristol, PA: Taylor Francis, 1994. pp. 40-41.
- ^ a b Hardman, Joel G., Lee E. Limbird, and Alfred G. Gilman, eds. "Rifampin." The Pharmacological Basis of Therapeutics. 10th ed. United States of America: The McGraw-Hill Companies, 2001. pp. 1277-1279.
- ^ O'Sullivan DM, McHugh TD, Gillespie SH (May 2005). "Analysis of rpoB and pncA mutations in the published literature: an insight into the role of oxidative stress in Mycobacterium tuberculosis evolution?". J. Antimicrob. Chemother. 55 (5): 674–9. doi:. PMID 15814606.
- ^ a b Collins, R Douglas. Atlas of Drug Reactions. New York, NY: ChurchillLivingstone, 1985. pp. 123.
- ^ Stockley, Ivan H. "Anticoagulant Drug Interactions." Drug Interactions. 3rd ed. Boston: Blackwell Scientific Publications, 1994. pp. 274-275.
